Instrument Inactif

Communiqués Biocorrx Inc Other OTC

Actions

US09073C1062

Installations et services en soins de santé

Communiqués

10/12	BioCorRx Inc. to Present at the Life Sciences Virtual Investor Forum December 11th	AQ
15/08/24	BioCorRx Reports Business Update for the Second Quarter of 2024	AQ
16/05/24	BioCorRx Reports Business Update for the First Quarter of 2024	AQ
03/04/24	BioCorRx Pharmaceuticals Inc. Awarded New Patent for Novel Compound to Treat Pain, Depression, and Schizophrenia	AQ
02/04/24	BioCorRx Reports Business Update for 2023	AQ
28/02/24	BioCorRx Pharmaceuticals Inc. Awarded NIDA Grant of Approximately $11 million Over Three Years for Research on BICX104, a Naltrexone Implant in Combination with Bupropion for the Treatment of MUD	AQ
08/02/24	BioCorRx Pharmaceuticals Inc. Appoints Neuroscientist Dr. Kate DeVarney to the Board of Directors	AQ
09/01/24	BioCorRx Appoints Renowned Investment and Capital Markets Executive Louis Lucido as President	AQ
15/12/23	BioCorRx : Material Agreement - Form 8-K	PU
14/11/23	BioCorRx Reports Business Update for the Third Quarter of 2023	AQ
15/08/23	BioCorRx Submits Expanded Access Treatment Protocol to FDA for BICX104, Implantable Biodegradable Naltrexone Pellet for Treatment of Opioid Use Disorder	AQ
14/08/23	BioCorRx Reports Business Update for the Second Quarter of 2023	AQ
18/07/23	BioCorRx Submits Fast Track Application to FDA for BICX104, an Implantable Biodegradable Naltrexone Pellet for The Treatment of Opioid Use Disorder	AQ
16/05/23	BioCorRx Provides Business Update for the First Quarter of 2023	AQ
11/04/23	BIOCORRX INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)	AQ
05/04/23	BIOCORRX INC. : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Financial Statements and Exhibits (form 8-K)	AQ
03/04/23	BioCorRx Provides Business Update for 2022	AQ
31/03/23	BIOCORRX INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	AQ
07/03/23	BioCorRx Announced Interim Positive Safety and Pharmacokinetic Results of Phase 1 Clinical Trial at 4th Annual NIH HEAL Initiative Investigator Meeting	AQ
23/02/23	BioCorRx Attended 4th Annual NIH HEAL Initiative Investigator Meeting; Shares Update on BICX104 Data	AQ
30/01/23	BioCorRx to Present at Sequire Biotechnology Conference on February 2nd	AQ
27/01/23	BioCorRx to Present at Sequire Biotechnology Conference on February 2nd	AQ
24/01/23	BioCorRx Appoints Pharmaceutical & Finance Veteran Harsha Murthy to the Board of Directors	AQ
23/01/23	BIOCORRX INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)	AQ
19/01/23	BioCorRx Announces Completion of Treatment Phase of Study Subjects and Preliminary Safety Data from Phase I Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder	AQ